Use the hyperlinks, where available to access additional clinical trial information.
A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Antibody
BeiGene Australia Pty Ltd
People that are eligible to join this trial will be randomly allocated into one of two arms. In the experimental arm (Arm A), participants will receive 200mg intravenous tislelizumab once every three weeks, in combination with 100mg oral sitravatinib once a day. In the comparator arm (Arm B), participants will receive 75mg/m2 intravenous docetaxel once every three weeks. In both arms of the trial, treatment will be administered until progressive disease or intolerable toxicity.